Optinose announced that the phase III ReOpen1 clinical trial of Xhance (fluticasone propionate) Exhalation Delivery System in chronic sinusitis met both of its co-primary endpoints.
Optinose announced the statistically significant benefits of Xhance (fluticasone propionate nasal spray) in the phase III ReOpen2 trial for both the symptoms co-primary endpoint and the CT scan co-primary endpoint.
Optinose , a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced the FDA has approved Xhance (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.